药物性胆管损伤:进展与挑战  

Drug-induced bile duct injury: progress and challenges

作　　者：李东良 Li Dongliang(Department of Hepatobiliary Disease,900th Hospital of Joint Logistics Support Force(Fuzhou General Clinical Medical College of Fujian Medical University),Fuzhou 350025,China)

机构地区：[1]联勤保障部队第九○○医院(福建医科大学福总临床医学院)肝胆内科,福州350025

出　　处：《中华肝脏病杂志》2023年第4期339-344,共6页Chinese Journal of Hepatology

摘　　要：药物性胆管损伤是一种特殊类型的药物性肝损伤,主要有两种病理类型即胆管减少或胆管消失综合征和继发性硬化性胆管炎。但近年来引起胆管损伤的新药物报道不断增多,这些药物引起的胆管损伤具有不同的临床病理特点及新的发病机制。现着重对药物性胆管损伤病因、发病机制及诊断治疗等进展和挑战进行总结分析。Drug-induced bile duct injury is a specific kind of drug-induced liver injury that has two main pathological types,namely ductopenia,or vanishing bile duct syndrome,and secondary sclerosing cholangitis.However,in recent years,the reports of new drugs that cause bile duct injury have been constantly increasing,and these drugs have different clinicopathological features and a novel pathogenesis.Therefore,this paper summarizes and analyzes the progress and challenges in the etiology,pathogenesis,diagnosis and treatment,and other aspects of drug-induced bile duct injury.

关 键 词：胆管消失综合征 继发性硬化性胆管炎 免疫性胆管炎 进展 

分 类 号：R575.7[医药卫生—消化系统]